CJC-1295: Hormonal Effects Without Long-Term Data CJC-1295 is an engineered analog of human growth hormone-releasing hormone (GHRH)
For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]
The majority of these events were mild to moderate in severity and transient, occurring during dose escalation and resolving over days to weeks as participants adapted
For diabetes management, less frequent dosing could result in suboptimal glycemic control, with potential increases in HbA1c levels
The additional acetyl group stabilises the S-acetylglutathione, allowing it to be better absorbed
They may be different in color, size, shape, and non-active fillers
